New pill targets gene flaws in hard-to-treat bile duct cancer

NCT ID NCT06777316

First seen Apr 18, 2026 · Last updated Jun 16, 2026 · Updated 10 times

Summary

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tried standard treatments will take the pill, and researchers will monitor safety, side effects, and how well it shrinks or controls the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fox Chase cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah, 84112, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Princess Margaret Cancer Centre - UHN

    Toronto, Ontario, M5G 2C4, Canada

  • Stanford Cancer Institute

    Palo Alto, California, 94305, United States

  • Taussig Cancer Center - Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • The Christ Hospital

    Cincinnati, Ohio, 45219, United States

  • University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.